The agreement was presented in the presence of the two high-ranking leaders of Viet Nam and Russia during the event within the framework of the official visit to the Russian Federation by General Secretary To Lam from May 8 to 11, on the occasion of the 80th anniversary of the Victory of the Great Patriotic War and the 75th anniversary of the Viet Nam-Russia diplomatic relations.
According to the cooperation agreement, the two sides will discuss establishing a foundation for deep cooperation on high technology in the biomedical field, focusing on research, investment, technology transfer and trade of biological medicines and high-tech vaccines. In particular, VNVC's top expectation is to bring a potential cancer treatment vaccine to Viet Nam, based on modern mRNA technology recently announced by Russia.
Additionally, VNVC also signed a cooperation agreement with the Gamaleya National Research Centre for Epidemiology and Microbiology on scientific research cooperation and biotechnology development. VNVC also signed an agreement with the Russian pharmaceutical group Binnopharm.
Right after the signing ceremony, VNVC began scientific exchange activities with scientists from many research institutes and high-level hospitals of Russia to receive technology transfer for research, testing and production of vaccines using mRNA technology.
In particular, research and implementation of vaccine production according to the "comprehensive, completely closed” model in Viet Nam, focusing on pharmaceutical products that are Binnopharm's strengths, along with other important pharmaceutical products of Russia, focusing on high-tech cancer diagnosis and treatment.
Previously, in December 2024, the National Medical Research Centre for Radiology under the Russian Ministry of Health announced that the country was researching and developing a potential lung cancer vaccine, produced using advanced mRNA technology.
According to the cooperation agreement between RDIF and VNVC, Russia’s potential mRNA technology vaccines will soon be brought to Viet Nam by VNVC from the early clinical trial stage, so that patients have the opportunity to access more of the world's leading modern solutions with a very high success rate after treatment.
In addition, the Russian side conducting clinical trials of biological drugs and advanced technology vaccines in Viet Nam also helps the license registration and commercialisation of products faster and more conveniently, as soon as good results are achieved.
With this agreement, VNVC participates in clinical trial research and product commercialisation, producing them at the VNVC’s Vaccine and Biological Products Factory in Long An.
According to Ngo Chi Dung, Chairman of the Board of Directors and CEO of VNVC, Viet Nam records hundreds of thousands of new infection cases and deaths from cancer each year, this important cooperation agreement will open up new opportunities for cancer treatment with the first vaccine in the country, contributing to savings cost and improving the quality of life for patients. This event also affirms the strong efforts of Viet Nam's healthcare sector, of which VNVC is the representative, in international science, technology and investment cooperation in developing Viet Nam’s modern vaccine production capacity under the direction of the Resolution No. 57 of the Politburo.
